Title of article :
Radioiodine therapy for hyperthyroidism
Author/Authors :
فرد اصفهاني، پژمان نويسنده Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran Fard-Esfahani, Pezhman , بيكي ، داوود نويسنده , , فلاحي، بابك نويسنده موسسه تحقيقات پزشكي هسته اي-بيمارستان دكتر شريعتي-دانشگاه علوم پزشكي تهران Fallahi, B. , فرد اصفهاني، ارمغان نويسنده دانشگاه علوم پزشكي تهران,مركز تحقيقات پزشكي هسته اي، بيمارستان دكتر شريعي , , امامي اردكاني، عليرضا نويسنده بيمارستان دكتر شريعتي Emami-Ardakani, Alireza , انصاري ، مجتبي نويسنده ansari, mojtaba , افتخاري ، محمد 1329 نويسنده پزشکي ,
Issue Information :
فصلنامه با شماره پیاپی 36 سال 2011
Pages :
12
From page :
1
To page :
12
Abstract :
Radioiodine therapy is the safest, simplest, least expensive and most effective method for treatment of hyperthyroidism. The method employed in this research was a systematic bibliographic review, in which only valid studies or the clinically detailed enough open-labeled studies using validated scales were used. Iodine-131 (I-131) acts by the destructive effect of short-range beta radiation on thyroid cells. Indications for radioiodine therapy include toxic nodules (in which I-131 is the first choice of treatment), recurrent hyperthyroidism after antithyroid treatment or surgery, intolerance to antithyroid therapy due to side-effects and patient preference. Due to difficulties in previous methods for dose determination, fixed dose method of I-131 is now considered the best practical method for radioiodine therapy in primary hyperthyroidism. Absolute contraindications for radioiodine treatment are pregnancy and lactation. In pediatric patients, radioiodine therapy can be used, but is mainly considered in recurrent toxic goiter and when antithyroid medication is ineffective. There is no clear evidence indicative of carcinogenic or teratogenic effect of this agent.
Journal title :
Iranian Journal of Nuclear Medicine
Serial Year :
2011
Journal title :
Iranian Journal of Nuclear Medicine
Record number :
690465
Link To Document :
بازگشت